TSCAN THERAPEUTICS INC
NASDAQ: TCRX (TScan Therapeutics, Inc.)
Last update: 6 hours ago0.381
-0.29 (-42.80%)
| Previous Close | 0.666 |
| Volume | 8,401,542 |
| Price / Sales | 12.15 |
| Price / Book | 0.650 |
| 52 Weeks Range |
| Operating Margin (TTM) | -1,669.74% |
| Diluted EPS (TTM) | -1.08 |
| Quarterly Revenue Growth (YOY) | 283.60% |
| Total Debt/Equity (MRQ) | 46.16% |
| Current Ratio (MRQ) | 8.55 |
| Operating Cash Flow (TTM) | -119.14 M |
| Levered Free Cash Flow (TTM) | -77.27 M |
| Return on Assets (TTM) | -30.45% |
| Return on Equity (TTM) | -78.93% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | TScan Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.23% |
| % Held by Institutions | 88.08% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Baker Bros. Advisors Lp | 30 Jun 2026 | 2,784,792 |
| Deer Management Co. Llc | 30 Jun 2026 | 1,245,504 |
| Jacobs Levy Equity Management, Inc | 30 Jun 2026 | 1,049,806 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |